

LIDDS appoints Mats Wiking as new CEO

GOTHENBURG, SWEDEN – The Board of Directors appoints Mats Wiking as new CEO and CFO from 1 September 2024.

Mats Wiking has long financial experience as finance director, controller and business developer from both small and medium sized companies and has the last few years mainly been working with company transactions.

“LIDDS’ operations have changed significantly the last year and Mats is the right person to lead the company going forward” says Daniel Lifveredson, Chairman of LIDDS’ Board of Directors. The Board of Directors and I would like to thank Jenni for her commitment and efforts during the years she has worked for LIDDS and wish her good luck in her new endeavors,” he continues.

Current CEO and CFO Jenni Björnulfson will assume a position in another company but will continue in her roles until 1 September to ensure a smooth transition to Mats Wiking.

This information is information that LIDDS is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-14 17:10 CEST.

For additional information, please contact

Jenni Björnulfson, CEO and CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratatumoral administration, with a maintained and controlled release for up to six months. LIDDS offers the NanoZolid technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. The company is listed on Nasdaq First North Growth market.

Attachments

LIDDS appoints Mats Wiking as new CEO